Cargando…

Cardiac side effects of trastuzumab in breast cancer patients – single centere experiences

AIM OF THE STUDY: The aim of this study was to present our own experiences concerning risk factors for cardiac side effects in the study group. MATERIAL AND METHODS: The study was performed in 120 patients with HER2-overexpressing breast cancer who received immunotherapy in the Clinical and Experime...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huszno, Joanna, Leś, Dominika, Sarzyczny-Słota, Danuta, Nowara, Elżbieta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2013
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3685367/ https://www.ncbi.nlm.nih.gov/pubmed/23788989 http://dx.doi.org/10.5114/wo.2013.34624

Ejemplares similares

Adult Wilms’ tumor – diagnosis and current therapy
por: Huszno, Joanna, et al.
Publicado: (2013)

The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab
por: Huszno, Joanna, et al.
Publicado: (2015)

Unfavorable prognosis of nephroblastoma in adults
por: Huszno, Joanna, et al.
Publicado: (2013)

Risk factors for disease progression in HER2-positive breast cancer patients based on the location of metastases
por: Huszno, Joanna, et al.
Publicado: (2015)

Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients
por: Huszno, Joanna, et al.
Publicado: (2016)

Outcome of COVID-19 infection in cancer patients during active systemic anticancer treatment. Single-institution experience. A retrospective analysis
por: Nowara, Elżbieta, et al.
Publicado: (2021)

The risk factors of toxicity during chemotherapy and radiotherapy in breast cancer patients according to the presence of BRCA gene mutation
por: Huszno, Joanna, et al.
Publicado: (2015)

Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
por: Nowara, Elzbieta, et al.
Publicado: (2016)

Treatment related toxicity in BRCA1-associated epithelial ovarian cancer – is DNA repairing impairment associated with more adverse events?
por: Badora-Rybicka, Agnieszka, et al.
Publicado: (2016)

Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer
por: Badora-Rybicka, Agnieszka, et al.
Publicado: (2016)

Mucin secretion activity of gastric cancer as a prognostic factor: a clinicopathological analysis
por: Huszno, Joanna, et al.
Publicado: (2012)

Checkpoint Kinase 2 (CHEK2) Mutation in Renal Cell Carcinoma: A Single-Center Experience
por: Huszno, Joanna, et al.
Publicado: (2018)

Chemotherapy for gastric cancer patients – time for personalization in medicine?
por: Nowara, Elżbieta, et al.
Publicado: (2012)

Early cardiac toxicity following adjuvant radiotherapy of left-sided breast cancer with or without concurrent trastuzumab
por: Cao, Lu, et al.
Publicado: (2015)

Impact of educational differences as measure of socioeconomic status on survival for breast cancer patients
por: Nowara, Elżbieta, et al.
Publicado: (2012)

Metaplastic breast carcinomas – analysis of prognostic factors in a case series
por: Nowara, Elżbieta, et al.
Publicado: (2014)

Cardiotoxicity of trastuzumab emtansine (T-DM1): a single-center experience
por: Acibuca, Aynur, et al.
Publicado: (2021)

Pharmacodynamic modeling of cardiac biomarkers in breast cancer patients treated with anthracycline and trastuzumab regimens
por: de Vries Schultink, Aurelia H. M., et al.
Publicado: (2018)

Long-term tolerance and cardiac function in breast cancer patients receiving trastuzumab therapy
por: Huang, Ping, et al.
Publicado: (2016)

Cardiac toxicity of trastuzumab in elderly patients with breast cancer
por: Denegri, Andrea, et al.
Publicado: (2016)

Association between obesity and trastuzumab-related cardiac toxicity in elderly patients with breast cancer
por: Wang, Hai-Yan, et al.
Publicado: (2017)

The relationship between 6-thioguanine levels and remission outcomes in children with autoimmune hepatitis. Single center experience
por: Kaps-Kopiec, Dominika, et al.
Publicado: (2023)

Clinicopathological characteristics of breast cancer patients with NOD2 mutation according to age
por: Huszno, Joanna, et al.
Publicado: (2020)

IL-15 enhances the anti-tumor activity of trastuzumab against breast cancer cells but causes fatal side effects in humanized tumor mice (HTM)
por: Wege, Anja K, et al.
Publicado: (2016)

Surgical treatment of primary cardiac tumors: 20-year single center experience
por: Děrgel, Martin, et al.
Publicado: (2022)

Trastuzumab in advanced breast cancer – a decade of experience in Germany
por: Jackisch, Christian, et al.
Publicado: (2014)

Axitinib in metastatic renal cell carcinoma: single center experience
por: Buraczewska, Agnieszka, et al.
Publicado: (2017)

The impact of ERBB-family germline single nucleotide polymorphisms on survival response to adjuvant trastuzumab treatment in HER2-positive breast cancer
por: Toomey, Sinead, et al.
Publicado: (2016)

Biomarkers of Trastuzumab-Induced Cardiac Toxicity in HER2- Positive Breast Cancer Patient Population
por: Grela-Wojewoda, Aleksandra, et al.
Publicado: (2022)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group
por: Mackey, J.R., et al.
Publicado: (2008)

Overall survival analysis of > 65-year-old patients with breast cancer based on their molecular, clinicopathological and laboratory factors
por: Huszno, Joanna, et al.
Publicado: (2022)

Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer
por: Palmieri, Carlo, et al.
Publicado: (2015)

Trastuzumab deruxtecan for breast cancer
Publicado: (2022)

Cardiac catheterisation in nonagenarians: Single center experience
por: Ohlow, Marc-Alexander, et al.
Publicado: (2012)

Effectiveness of neoadjuvant trastuzumab and chemotherapy in HER2-overexpressing breast cancer
por: Natoli, Clara, et al.
Publicado: (2013)

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
por: Canonici, Alexandra, et al.
Publicado: (2013)

Tunicamycin enhances the antitumor activity of trastuzumab on breast cancer in vitro and in vivo
por: Han, Xiqian, et al.
Publicado: (2015)

Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer
por: Terrell-Hall, Tori B., et al.
Publicado: (2017)

Early immune modulation by single-agent trastuzumab as a marker of trastuzumab benefit
por: Triulzi, Tiziana, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5smaicnocq4g4qnh29b21m2nbs